Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $28.32 and last traded at $28.41, with a volume of 74570 shares changing hands. The stock had previously closed at $31.48.
Analyst Ratings Changes
A number of research firms have recently commented on GPCR. JMP Securities reaffirmed a "market outperform" rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday. HC Wainwright initiated coverage on shares of Structure Therapeutics in a research note on Wednesday, December 4th. They set a "buy" rating and a $80.00 price target for the company. Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an "overweight" rating and a $118.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics currently has an average rating of "Buy" and an average target price of $86.50.
Read Our Latest Analysis on Structure Therapeutics
Structure Therapeutics Price Performance
The stock has a market capitalization of $1.60 billion, a P/E ratio of -37.70 and a beta of -3.41. The company's 50 day simple moving average is $35.71 and its two-hundred day simple moving average is $39.09.
Institutional Investors Weigh In On Structure Therapeutics
A number of large investors have recently bought and sold shares of GPCR. Sandia Investment Management LP acquired a new position in Structure Therapeutics in the second quarter worth $39,000. Assetmark Inc. raised its holdings in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after buying an additional 719 shares during the last quarter. Quarry LP acquired a new position in Structure Therapeutics during the 2nd quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after acquiring an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC acquired a new stake in Structure Therapeutics in the 3rd quarter valued at about $202,000. 91.78% of the stock is currently owned by institutional investors.
Structure Therapeutics Company Profile
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Read More
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
